This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Latest News

European Commission approval for self-administration of Xolair® across all indications

Monday 17th December 2018
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
Mon, 29 Oct 2018
Medicines watchdog seizes over £2m counterfeit medicines in UK drugs bust
Fri, 26 Oct 2018
The study, by Erasmus University Medical Centre (EUMC), looked at data from 20 European countries, including the United Kingdom, France and the Netherlands.
Fri, 26 Oct 2018
Researchers have said the next step is to explore the potential anti-inflammatory properties of cannabis to treat inflammatory bowel disease
Thu, 25 Oct 2018
New study data also confirm efficacy for Stelara (ustekinumab) in Crohn's disease patients who are naïve and refractory/intolerant to tumour necrosis factor antagonist treatment